Letter--The Authors Respond

J Manag Care Spec Pharm. 2019 Sep;25(9):1028-1030. doi: 10.18553/jmcp.2019.25.9.1028.

Abstract

No additional funding was received for the writing of this letter. The published study referred to in this letter was funded by Janssen Scientific Affairs, which employs Maiese and funded Cornerstone Research Group, a health economic consulting group, to conduct the study. Grima is a founding partner of Cornerstone Research Group, which employs Hollmann, Goyert, and Moldaver.

MeSH terms

  • Humans
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / economics*
  • Progression-Free Survival
  • Quality of Life
  • United States
  • United States Food and Drug Administration